Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy

Clinical Pharmacokinetics

Volumn 44, Issue 6, 2005, Pages 591-625

  Barrett, Jeffrey S ^a,d   Labbé, Line ^b   Pfister, Marc ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RESCRIPT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ANALYTIC METHOD; BLOOD SAMPLING; CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE MARKER; DRUG CHOICE; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG MONITORING; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; PATIENT COMPLIANCE; POPULATION MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SAMPLING; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG MONITORING; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; POPULATION;

EID: 22244480365     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544060-00003     Document Type: Review

References (173)

1. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9 (7): 867-73
2. Pfister M, Labbe L, Lu JF, et al. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002; 72 (2): 133-41
3. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87 (7): 803-7
4. Korber BT, Allen EE, Farmer AD, et al. Heterogeneity of HIV-1 and HIV-2. AIDS 1995; 9 Suppl. A: S5-18
5. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47 (1): 130-7
6. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36 (4): 289-304
7. Physicians' desk reference, 58th ed. Montvale (NJ): Thomson Healthcare, Inc., 2004
8. Lu JF, Blaschke TF, Flexner C, et al. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. Drug Metab Dispos 2002; 30 (12): 1455-61
9. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16 (10): 1331-40
10. Jackson KA, Rosenbaum SE, Kerr BM, et al. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000; 44 (7): 1832-7
11. Hsu A, Granneman FR, Japour A. Evaluation of potential ritonavir and indinavir combination BID regimens [abstract]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
12. Vanhove GF, Gries JM, Verotta D, et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997; 41 (11): 2433-8
13. Vanhove GF, Kastrissios H, Gries JM, et al. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997; 41 (11): 2428-32
14. Lunn DJ, Aarons L. The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis. J Pharmacokinet Biopharm 1998; 26 (1): 47-74
15. Drusano GL, D'argenio DZ, Preston SL, et al. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 2000; 44 (6): 1655-9
16. Weller S, Radomski KM, Lou Y, et al. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2000; 44 (8): 2052-60
17. Drusano GL, Yuen GJ, Morse G, et al. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob Agents Chemother 1992; 36 (6): 1280-3
18. Adams JM, Shelton MJ, Hewitt RG, et al. Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother 1998; 42 (4): 821-6
19. Harb GE, Mandema JW, Delahunty T, et al. Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection [letter]. J Infect Dis 1996; 173 (1): 273
20. Pai SM, Shukla UA, Grasela TH, et al. Population pharmacokinetic analysis of didanosine (2′,3′-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J Clin Pharmacol 1992; 32 (3): 242-7
21. Piscitelli SC, Amatea MA, Vogel S, et al. Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. Antimicrob Agents Chemother 1996; 40 (1): 161-5
22. Zhou XJ, Sheiner LB, D'aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 1999; 43 (1): 121-8
23. Pereira AS, Smeaton LM, Gerber JG, et al. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS Clinical Trials Group Study 850). J Infect Dis 2002; 186 (2): 198-204
24. Moore KH, Yuen GJ, Hussey EK, et al. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 1999; 43 (12): 3025-9
25. Zhang L, Price R, Aweeka F, et al. Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study. Eur J Pharm Sci 2001; 12 (4): 377-85
26. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39 (10): 2309-15
27. Gries JM, Troconiz IF, Verotta D, et al. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex. Clin Pharmacol Ther 1997; 61 (1): 70-82
28. Adams JM, Shelton MJ, Hewitt RG, et al. Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother 1998; 42 (2): 409-13
29. Collart L, Blaschke TF, Boucher F, et al. Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. Dev Pharmacol Ther 1992; 18 (1-2): 71-80
30. Mirochnick M, Capparelli E, Dankner W, et al. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42 (4): 808-12
31. Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142 (1): 47-52
32. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003; 43 (2): 133-40
33. Sasomsin P, Mentre F, Diquet B, et al. Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. Fundam Clin Pharmacol 2002; 16 (5): 347-52
34. Guidance for industry: exposure-response relationships. Study design, data analysis, and regulatory applications: draft guidance. Washington, DC: US Department of Health and Human Services, 2002 Mar
35. Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther 1990; 48 (2): 161-7
36. Mentre F, Escolano S, Diquet B, et al. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45 (5): 397-407
37. Polis MA, Piscitelli SC, Vogel S, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41 (8): 1709-14
38. Barrett JS, Joshi AS, Chai M, et al. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40 (11): 507-19
39. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73 (1): 20-30
40. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999; 48 (5): 712-5
41. De Maat MM, Huitema AD, Mulder JW, et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54 (4): 378-85
42. Soy D, Aweeka FT, Church JA, et al. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther 2003; 74 (6): 569-80
43. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26 (6): 552-61
44. Lown KS, Ghosh M, Watkins PB. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 1998; 26 (2): 185-7
45. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44 (2): 190-4
46. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26 (7): 609-16
47. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11 (4): F29-33
48. Yuen G, Anderson R, Daniels R. Investigations of nelfinavir mesylate (NFV) pharmacokinetics (PK) interactions with indinavir (IDV) and ritonavir (RTV) [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 2; Washington, DC
49. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 1999; 27 (8): 902-8
50. Srinivas RV, Middlemas D, Flynn P, et al. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42 (12): 3157-62
51. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14 (3): 237-42
52. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13 (13): 1623-7
53. Hoetelmans RM, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12 (11): F111-5
54. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 171 Suppl. 2: S99-112
55. Barbier O, Turgeon D, Girard C, et al. 3′-azido-3′- deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyl-transferase 2B7 (UGT2B7). Drug Metab Dispos 2000; 28 (5): 497-502
56. Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol 1995; 26 (7): 1469-75
57. Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine: an update. Clin Pharmacokinet 1996; 30 (4): 251-62
58. Piscitelli S, Vogel S, Sadler B. Effect of efavirenz (DMP266) in the pharmacokinetics of 141W94 in HIV infected patients [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 2-5; Chicago
59. Adkins JC, Noble S. Efavirenz. Drugs 1998; 56 (6): 1055-64
60. Sustiva™ (efavirenz) capsules (product information). Princeton (NJ): Bristol-Myers Squibb Company, 2000
61. Sahai J, Cameron W, Salgo M. Drug interaction study between saquinavir (SQV) and nevirapine (NVP) [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 2; Washington, DC
62. Gagnier P, Myers M, Lamson M. Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) in HIV-1 patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 2; Washington, DC
63. Lamson M, Gagnier P, Greguski R. Effect of nevirapine (NFP) on pharmacokinetics (PK) of ritonavir (RTV) in HIV-1 patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 2; Washington, DC
64. Merry C, Barry MG, Mulcahy F, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998; 12 (10): 1163-7
65. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Expert Opin Invest Drugs 1996; 5: 1183-99
66. Cox SR, Schneck DW, Herman BD. Delavirdine (DLV) and nefinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 2-5; Chicago
67. Cox SR, Ferry JJ, Batts DH. Delavirdine and marketed protease inhibitors: pharamcokinetic interaction studies in healthy volunteers [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 2; Washington, DC
68. Ferry JJ, Herman BD, Cox SR. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 2; Washington, DC
69. Morse GD, Shelton MJ, Hewitt RG. Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delavirdine [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 2-5; Chicago
70. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4 (11): 1302-7
71. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999; 96 (10): 5698-703
72. Fuzeon (enfuvirtide) prescribing information. Nutley (NJ): Roche Laboratories Inc, 2003
73. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337 (11): 725-33
74. Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186 (10): 1403-11
75. Wit FW, Van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179 (4): 790-8
76. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353 (9156): 863-8
77. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5 (5): 445-79
78. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters: I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980; 8 (6): 553-71
79. Hochhaus G, Barrett JS, Derendorf H. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J Clin Pharmacol 2000; 40 (9): 908-17
80. Guidance for industry: population pharmacokinetics. Washington, DC: US Department of Health and Human Services, 1999
81. Ellner PD, Neu HC. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 1981; 246 (14): 1575-8
82. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47 (1): 350-9
83. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46 (3): 746-54
84. Letendre SL, Capparelli EV, Ellis RJ, et al. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 2000; 44 (8): 2173-5
85. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000; 14 (18): 2869-76
86. Martin C, Sonnerborg A, Svensson JO, et al. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS 1999; 13 (10): 1227-32
87. Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther 1999; 66 (1): 16-24
88. Marimoutou C, Chene G, Mercie P, et al. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr 2001; 27 (2): 161-7
89. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126 (12): 946-54
90. Thiebaut R, Chene G, Jacqmin-Gadda H, et al. Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine co-hort, 1996-2001. J Acquir Immune Defic Syndr 2003; 33 (3): 380-6
91. Ormaasen V, Bruun JN, Sandvik L, et al. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection. Scand J Infect Dis 2003; 35 (6-7): 383-8
92. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29 (4): 346-55
93. Malhotra U, Bosch RJ, Chan E, et al. Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease. J Infect Dis 2004; 189 (3): 515-9
94. Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003; 8 (5): 427-34
95. Falloon J, Ait-Khaled M, Thomas DA, et al. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16 (3): 387-96
96. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16 (5): 727-36
97. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14 (10): 1333-9
98. Kulkosky J, Sullivan J, Xu Y, et al. Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo. Virology 2003; 314 (2): 617-29
99. Hu DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV: the importance of global surveillance for diagnostics, research, and prevention. JAMA 1996; 275 (3): 210-6
100. Moore J, Anderson R. The WHO and why of HIV vaccine trials. Nature 1994; 372 (6504): 313-4
101. Darby SC, Doll R, Thakrar B, et al. Time from infection with HIV to onset of AIDS in patients with haemophilia in the UK. Stat Med 1990; 9 (6): 681-9
102. McDonald RA, Mayers DL, Chung RC, et al. Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol 1997; 71 (3): 1871-9
103. Lukashov VV, Kuiken CL, Goudsmit J. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J Virol 1995; 69 (11): 6911-6
104. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41 (5): 898-905
105. Wade JR, Kelman AW, Howie CA, et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993; 21 (2): 209-22
106. FDA. Current modalities used in the treatment of HIV infection [online]. Available from URL: http://www.fda.gov/oashi/aids/status.html [Accessed 2005 Apr 22]
107. Perry CM, Balfour JA. Didanosine: an update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 1996; 52 (6): 928-62
108. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic: pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20 (5): 511-28
109. Drusano GL, Moore KH, Kleim JP, et al. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46 (3): 913-6
110. Jackson RC. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity. J Pharmacokinet Biopharm 1997; 25 (6): 713-30
111. Verotta D, Schaedeli F. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. Math Biosci 2002; 176 (2): 163-83
112. Drusano GL, Bilello JA, Preston SL, et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis 2001; 183 (7): 1126-9
113. Little RJA. Regression with missing X's: a review. J Am Stat Assoc 1992; 87: 1227-37
114. Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley & Sons, 1986
115. Labbe L, Hammer SM, Mellors JW, et al. A Markov model for the effect of covariates including drug adherence on longitudinal viral response in HIV patients [abstract]. 105th American Society for Clinical Pharmacology and Therapeutics Meeting; 2004 Mar 24-27; Miami Beach
116. Hayes KG, Perl ML, Efron B. Application of the bootstrap statistical method to the tau-decay-mode problem. Phys Rev D Part Fields 1989; 39 (1): 274-9
117. Egger M, Junghans C, Friis-Moller N, et al. Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS 2001; 15 Suppl. 5: S193-201
118. Lu J, Gries JM, Verotta D, et al. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn 2001; 28 (4): 343-62
119. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17 (20): 2313-33
120. Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. Washington, DC: US Department of Health and Human Services, 1998
121. King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet 2002; 41 (14): 1115-33
122. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387 (6629): 188-91
123. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271 (5255): 1582-6
124. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387 (6629): 183-8
125. Moroni M, Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. AIDS 2003; 17 Suppl. 1: S51-64
126. Pfister M, Zhang L, Hammarlund-Udenaes M, et al. Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. Antimicrob Agents Chemother 2003; 47 (1): 138-43
127. Nowak MA, May RM. Mathematical biology of HIV infections: antigenic variation and diversity threshold. Math Biosci 1991; 106 (1): 1-21
128. Nowak MA, Bonhoeffer S, Shaw GM, et al. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J Theor Biol 1997; 184 (2): 203-17
129. Wein LM, D'amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998; 192 (1): 81-98
130. Stafford MA, Corey L, Cao Y, et al. Modeling plasma virus concentration during primary HIV infection. J Theor Biol 2000; 203 (3): 285-301
131. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373 (6510): 117-22
132. Wu H, Ding AA, De Gruttola V. Estimation of HIV dynamic parameters. Stat Med 1998; 17 (21): 2463-85
133. Gieschke R, Fotteler B, Buss N, et al. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37 (1): 75-86
134. Stein DS, Drusano GL. Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrob Agents Chemother 1997; 41 (2): 449-53
135. Stein DS, Fish DG, Bilello JA, et al. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10 (5): 485-92
136. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346 (26): 2039-46
137. Huang Y, Rosenkranz SL, Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci 2003; 184 (2): 165-86
138. Lockwood PA, Cook JA, Ewy WE, et al. The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. Pharm Res 2003; 20 (11): 1752-9
139. Kuti JL, Dandekar PK, Nightingale CH, et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43 (10): 1116-23
140. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23 (5): 386-95
141. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161 (16): 1962-8
142. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13 (9): 1099-107
143. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279 (24): 1977-83
144. Hirsch MS, Conway B, D'aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society: USA Panel. JAMA 1998; 279 (24): 1984-91
145. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA 1996; 276 (24): 1955-6
146. Gallego O, De Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001; 15 (13): 1701-6
147. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14 (4): 357-66
148. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17 (13): 1925-32
149. Pekovic V, Mayanja H, Vjecha M, et al. Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration. J Clin Epidemiol 1998; 51 (7): 597-607
150. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134 (10): 968-77
151. Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods. AIDS Read 1999; 9 (5): 329-38
152. Vrijens B. Analyzing time-varying patterns of human exposure to xenobiotics and their biomedical impact. Ghent: University of Ghent, 2002
153. Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996; 24 (3): 265-82
154. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30 (1): 83-103
155. Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998; 12 (17): 2295-303
156. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15 Suppl. 5: S171-81
157. Burger D, Hugen P, Droste J. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naïve patients improves therapeutic outcome after 1 year: results from ATHENA [abstract]. First IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul 8-11, Buenos Aires
158. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000; 30 Suppl. 2: S123-9
159. Van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14 (8): F77-82
160. Soldin OP, Elin RJ, Soldin SJ. Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome: quo vadis? Arch Pathol Lab Med 2003; 127 (1): 102-5
161. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001; 23 (6): 591-605
162. Van Heeswijk RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit 2002; 24 (3): 323-31
163. Trotta MP, Ammassari A, Cozzi-Lepri A, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS 2003; 17 (7): 1099-102
164. Perno CF, Ceccherini-Silberstein F, De Luca A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr 2002; 31 Suppl. 3: S118-22
165. Boffito M, Back DJ, Hoggard PG, et al. Intra-individual variability in
166. Noormohamed SE, Henry WK, Rhame FS, et al. Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother 1995; 39 (12): 2792-7
167. Food and Drug Administration. New drug, antibiotic, and biological drug product regulations; accelerated approval: final rule. Fed Regist 1992; 57: 58942-60
168. James JS. Editorial: time to end the death trials. AIDS Treat News 1996 Aug 2; (252): 1-4
169. Mitka M. Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish. JAMA 2003; 289 (24): 3227-9
170. Orlando VI. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation? Am J Law Med 1999; 25 (4): 543-68
171. Pau AK. Antiretroviral therapy-associated serious and life-threatening toxicities. Curr Infect Dis Rep 2003; 5 (5): 429-38
172. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Washington, DC: US Department of Health and Human Services, 1999
173. Guidance for industry: pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact in dosing and labeling. Washington, DC: US Department of Health and Human Services, 1998